ASH 2024: Polycythemia Vera and Myelofibrosis: Current and Future Standards of Care
home / peer-exchange / ash-2024-polycythemia-vera-and-myelofibrosis-current-and-future-standards-of-care
Panelists discuss how recent advancements in the treatment of polycythemia vera and myelofibrosis, including the role of JAK inhibitors, cytoreductive therapy, and emerging therapies, are shaping current clinical practice and guiding personalized treatment strategies.
EP. 1: Initial Treatment Strategies for Polycythemia Vera
December 23rd 2024Panelists discuss how they approach the evaluation and diagnosis of polycythemia vera (PV), including key clinical manifestations, and how they assess disease risk to determine initial treatment strategies based on NCCN guidelines, considering factors that differentiate low-risk from high-risk PV.
